SG Americas Securities LLC Acquires 96,593 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

SG Americas Securities LLC raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 110.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 184,196 shares of the medical equipment provider’s stock after acquiring an additional 96,593 shares during the period. SG Americas Securities LLC owned approximately 0.09% of Zimmer Biomet worth $19,884,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ZBH. Price T Rowe Associates Inc. MD boosted its holdings in Zimmer Biomet by 12.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider’s stock valued at $1,404,638,000 after purchasing an additional 1,215,935 shares in the last quarter. American Century Companies Inc. boosted its holdings in Zimmer Biomet by 12.6% during the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock valued at $701,521,000 after purchasing an additional 722,041 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in Zimmer Biomet by 6.7% during the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider’s stock valued at $365,163,000 after purchasing an additional 211,637 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Zimmer Biomet by 5.3% during the second quarter. Van ECK Associates Corp now owns 3,325,598 shares of the medical equipment provider’s stock valued at $360,927,000 after purchasing an additional 167,038 shares in the last quarter. Finally, Boston Partners boosted its holdings in Zimmer Biomet by 26.3% during the first quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider’s stock valued at $437,413,000 after purchasing an additional 691,191 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 0.5 %

NYSE ZBH traded up $0.49 on Friday, reaching $104.68. The company had a trading volume of 1,449,205 shares, compared to its average volume of 1,497,624. The firm has a market capitalization of $21.54 billion, a price-to-earnings ratio of 22.66, a price-to-earnings-growth ratio of 1.94 and a beta of 1.02. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $133.90. The company’s fifty day moving average is $109.19 and its 200-day moving average is $114.16.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, topping the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.94 billion. During the same period in the previous year, the firm posted $1.82 EPS. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s payout ratio is 20.78%.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of recent research reports. Royal Bank of Canada decreased their price objective on Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Canaccord Genuity Group cut their target price on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, September 10th. Wolfe Research began coverage on shares of Zimmer Biomet in a research note on Tuesday, September 10th. They issued a “peer perform” rating for the company. BTIG Research cut their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Citigroup cut their target price on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $125.05.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.